C O M M U N I C A T I O N S
14, the oxime -OH moiety preferentially engages in an O-H‚‚‚N
hydrogen bond with the former, which is in line with the MEP-
guided hierarchy. The remaining pyridyl site could have become a
participant in either a halogen bond or a hydrogen bond involving
an acidic C-H group. In this race for the py group, only the iodo
substituent was strong enough to compete successfully with the
C-H imine. This structural advantage of N‚‚‚I bonds over N‚‚‚Br
bonds is also reflected by the fact that the CSD11 only contains 13
molecular cocrystals assembled through N‚‚‚Br interactions, whereas
there are more than 50 cocrystals constructed using N‚‚‚I bonds.
This structural study, albeit performed on a relatively small
number of compounds, indicates that a good hydrogen-bond donor
is likely to be very competitive for a N-heterocyclic moiety, even
in the presence of a fluoro-activated organoiodine. The latter group
is, however, capable of displacing a less conventional hydrogen-
bond donor such as the C-H imine moiety. Furthermore, since
C-Br is a significantly weaker Lewis acid than the C-I group, it
does not form a halogen bond that can compete with the C-H‚‚‚N
hydrogen bonds in 12 and 13. The structures presented herein are
primarily governed by hydrogen and halogen bonds but the final
crystal structure is of course the result of a balance of numerous
weak and rather unpredictable interactions (fluorine segregation,12
however, does not seem to play a discernible role in this series of
compounds).
Figure 4. (a) The 1:1 cocrystal of 12; (b) extended architecture through
multiple hydrogen bonds.
Figure 5. (a) The 1:1 cocrystal of 13; (b) 1-D chain produced through
multiple hydrogen bonds.
Systematic cocrystallization reactions that probe the balance
between, and structural outcome of, a mixture of hydrogen bonds/
halogen bonds will undoubtedly assist in developing versatile
strategies for the future assembly of discrete supermolecules and
heteromeric molecular architectures.
Acknowledgment. We are grateful for the financial support
from NSF (Grant CHE-0316479) and the Terry C. Johnson Center
for Basic Cancer Research and for a DURIP-ARO instrumentation
grant.
Supporting Information Available: Detailed experimental pro-
cedures for compounds 1-4, along with crystallographic data and CIF
files for 3, 4, 12, 13, and 14. This material is available free of charge
Figure 6. (a) The 1:1 cocrystal of 14; (b) tetrameric supermolecule
constructed through hydrogen bonds and halogen bonds.
References
(1) Making Crystals by Design-from Molecules to Molecular Materials,
Methods, Techniques, Applications; Grepioni, F., Braga, D., Eds.; Wiley-
VCH: Weinheim, Germany, 2007; pp 209-240.
In 13 (the 1:1 cocrystal of 1 and 3) the oxime -OH proton forms
a hydrogen bond to the benzimidazole site, (O‚‚‚N, 2.675(3) Å),
as was the case in 12, which leaves the pyridine moiety free to
pick up the imine proton, a significantly weaker hydrogen-bond
donor, (C‚‚‚N, 3.42 Å), resulting in a 1-D extended architecture,
(Figure 5a and b).
Although N‚‚‚Br halogen bonds are known to be of sufficient
strength to drive the assembly of molecular cocrystals,10 the -Br
moiety cannot successfully compete with an acidic C-H for the
py site in 13.
(2) Desiraju, G. R. Angew. Chem., Int. Ed. Engl. 1995, 34, 2311.
(3) (a) Aakero¨y, C. B.; Beatty, A. M.; Helfrich, B. A. Angew. Chem., Int.
Ed. 2001, 40, 3240. (b) Aakero¨y, C. B.; Desper, J.; Urbina, J. F. Chem.
Commun. 2005, 2820. (c) Wuest, J. D. Chem. Commun. 2005, 5830. (d)
Trask, A. V.; Jones, W. Top. Curr. Chem. 2005, 254, 41. (e) Reddy, L.
S.; Babu, N. J.; Nangia, A. Chem. Commun. 2006, 1369.
(4) Metrangolo, P.; Neukirch, H.; Pilati, T.; Resnati, G. Acc. Chem. Res. 2005,
38, 386.
(5) (a) Walsh, R. B.; Padgett, C. W.; Metrangolo, P.; Resnati, G.; Hanks, T.
W.; Pennington, W. T. Cryst. Growth Des. 2001, 1, 165. (b) Corradi, E.;
Meille, S. V.; Messina, M. T.; Metrangolo, P.; Resnati, G. Angew. Chem.,
Int. Ed. 2000, 39, 1782.
(6) Spartan ’04; Wavefunction, Inc.: Irvine, CA, 2004.
In 14 (a 1:1 cocrystal of 1 and 4) a hydrogen bond is again
formed between the -OH oxime and benzimidazole moiety, (O‚‚‚N,
2.706(6) Å). However, this time the iodo-substituent in 4 (“acti-
vated” by four -F substituents), does form a halogen bond,
(N‚‚‚I(1), 2.888 Å; C-I‚‚‚N, 168°), with the remaining pyridyl
group resulting in a four-component supermolecule (Figure 6).
The benzimidazole moiety carries a larger negative MEP than
the pyridyl functionality, and in each of the three cocrystals 12-
(7) Hunter, C. A. Angew. Chem. Int. Ed. 2004, 43, 5310.
(8) This ranking is in agreement with a hydrogen-bond scale based upon ∆G
values for hydrogen-bonded complexes, see: Laurence, C.; Berthelot, M.
Perspect. Drug DiscoVery. Des. 2000, 18, 39.
(9) Desiraju, G. R.; Parthasarathy, R. J. Am. Chem. Soc. 1989, 111, 8725.
(10) Santis, A. D.; Forni, A.; Liantonio, R.; Metrangolo, P.; Pilati, T.; Resnati,
G. Chem. Eur. J. 2003, 9, 3974.
(11) ConQuest, version 1.8; Cambridge Structural Database: Cambridge, U.K.
(12) Dautel, O. J.; Fourmigue, M.; Faulques, F. CrystEngComm 2002, 4, 249.
JA073201C
9
J. AM. CHEM. SOC. VOL. 129, NO. 45, 2007 13773